All In Biotech

Drug Trial Radar · NCT06237231

Efficacy and Safety of DIT112 in the Treatment of Moderate to Severe Pain After Dental Surgery for the Extraction of Impacted Third Molars

Phase III, Multicenter, Double-blind, Triple-dummy, Randomized, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DIT112 in the Treatment of Moderate to Severe Pain After Dental Surgery for the Extraction of Impacted Third Molars

Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Feb 15, 2025

Primary completion

Mar 15, 2025

Study completion Apr 10, 2027

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Feb 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of DIT112 in adolescents and adults with acute pain after dental surgery for the extraction of impacted third molars.

Conditions

  • Moderate Pain
  • Severe Pain

Interventions

  • DIT112Drug

    DIT112 tablet

  • DIPYRONEDrug

    Dipyrone tablet 1.000mg

  • TRAMADOLDrug

    Tramadol tablet 50mg

  • DIT112 PlaceboDrug

    DIT112 placebo tablet

  • Dipyrone PlaceboDrug

    Dipyrone placebo tablet

  • Tramadol PlaceboDrug

    Tramadol placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total pain relief within four (04) hours after the first PSI administration, assessed using the area under the curve of pain interruption scores (TOTPAR0-4h).Time frame: 0-4 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.